A state of the art multiparametric flow cytometry analysis system for multidisciplinary stem cell research
Lead Research Organisation:
Newcastle University
Department Name: Institute of Human Genetics
Abstract
Stem cells are capable of essentially extensive growth whilst retaining the ability to differentiate into most of the cell types found in the adult but unless we can find ways to grow them in large numbers while directing them to differentiate into therapeutically useful cells much of this potential will not be realised. A major obstacle impacting the derivation of differentiated cell types from stem cells is that current in vitro differentiation strategies often only produced the desired cells in small numbers. This means they must be separated from the other cell types present and one of the best techniques we have for doing this is flow cytometry. This technology relies upon the binding of fluorescent labelled antibodies to the surfaces of our desired cells such that when they pass through the flow cytometer they can be separated from the others and retain their viability. If appropriate antibodies are available, up to 12 different colours can be analysed at any one time using the instrumentation detailed in this proposal and this offers us an unparalleled advantage in cell identification and separation. There are a number of active research groups at the Institute of Human Genetics investigating a range of differentiation protocols designed to produce useful cells from a range of stem cells and flow cytometry instrumentation is not only indispensable to this work but is also subject to very heavy demand. In view of this, a successful outcome of this proposal would greatly enhance our ability to develop useful techniques for stem cell differentiation that will ultimately benefit medical science in general.
Technical Summary
Stem cells, both embryonic and adult offer great promise for the development of therapeutic applications but for both of these stem cell types, separation of specific cells will be required. In the case of embryonic stem cells there is a need for culture strategies that can direct their differentiation towards therapeutically useful cells but currently available techniques produce heterogeneous mixtures from which we need to separate the desired cells. Adult stem cells exist in heterogeneous microenvironments or niches and again are often present in only very small numbers underlining the requirement for advanced separation technologies. Fluorescence activated cell sorting (FACS) is the most versatile method for separating such small numbers, provided that specific antibodies are available for the surface proteins of a specific cell type. A great advantage of FACS is that multiple antibodies labelled with different fluorochromes may be used in a single cell sample thereby increasing the total data available from a single experiment. Such multiparametric flow cytometry is cost effective in terms of antisera consumption and permits more detailed identification and isolation of rare cells but this requires the development of additional fluorescent labelled antibodies against proteins specific to these cells. This can only be achieved by increasing our understanding of stem cell biology which is a major focus of stem cell research at the Institute of Human Genetics. Stem cells of all types are difficult to grow in vitro hence a better understanding of the signal transduction mechanisms which promote pluripotency in embryonic stem cells and contribute to interaction with the niche for adult stem cells are an essential part of this proposal. Multiparametric flow cytometry will be an important part of this investigation since may use it for parallel examination of multiple intracellular proteins with small numbers of cells.
Publications
Adam S
(2017)
Concise Review: Getting to the Core of Inherited Bone Marrow Failures.
in Stem cells (Dayton, Ohio)
Allegrucci C
(2007)
Restriction landmark genome scanning identifies culture-induced DNA methylation instability in the human embryonic stem cell epigenome.
in Human molecular genetics
Armstrong L
(2010)
Human induced pluripotent stem cell lines show stress defense mechanisms and mitochondrial regulation similar to those of human embryonic stem cells.
in Stem cells (Dayton, Ohio)
Armstrong L
(2014)
Concise review: the epigenetic contribution to stem cell ageing: can we rejuvenate our older cells?
in Stem cells (Dayton, Ohio)
Atkinson SP
(2013)
Potential for pharmacological manipulation of human embryonic stem cells.
in British journal of pharmacology
Atkinson SP
(2008)
Epigenetic marking prepares the human HOXA cluster for activation during differentiation of pluripotent cells.
in Stem cells (Dayton, Ohio)
Atkinson SP
(2012)
A putative role for the immunoproteasome in the maintenance of pluripotency in human embryonic stem cells.
in Stem cells (Dayton, Ohio)
Barta T
(2016)
Brief Report: Inhibition of miR-145 Enhances Reprogramming of Human Dermal Fibroblasts to Induced Pluripotent Stem Cells.
in Stem cells (Dayton, Ohio)
Baud A
(2017)
Multiplex High-Throughput Targeted Proteomic Assay To Identify Induced Pluripotent Stem Cells.
in Analytical chemistry
Baylis O
(2011)
13 years of cultured limbal epithelial cell therapy: a review of the outcomes.
in Journal of cellular biochemistry
Description | The funding from this award has been used to establish the new multicolour state of the art flow cytometry system at the Institute of Genetic Medicine. This euqipment has provided a unique resource for Stem Cell groups in Newcastle and Durham University enabling research in areas of embryonic and somatic stem cell biology as well as developmental and cell biology projects across both campuses. The equipment is now part of the University wide flow cytometry core facility which is now self-funded through FEC based internal charging system. |
Exploitation Route | Through collaborative links with Guava and BD Biosciences, we test a range of monoclonal antibodies and cell surface markers prior to their commercialisation using funds obtained via the KTP scheme. The equipment purchased via this equipment award is now part of the University wide flow cytometry core facility which is now self-funded through FEC based internal charging system. |
Sectors | Leisure Activities including Sports Recreation and Tourism |
Description | 3D hiPSC derived laminated retina model |
Amount | £1,000,000 (GBP) |
Funding ID | NC/C016106/1 |
Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
Sector | Public |
Country | United Kingdom |
Start | 11/2017 |
End | 10/2020 |
Description | BBSRC Equipment Grant |
Amount | £141,849 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2008 |
End | 05/2009 |
Description | BBSRC project grant |
Amount | £460,000 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2012 |
End | 12/2014 |
Description | BBSRC strategic tools and objectives scheme |
Amount | £140,000 (GBP) |
Funding ID | BB/I02333X/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 07/2011 |
End | 07/2012 |
Description | BHF PROJECT GRANT |
Amount | £140,000 (GBP) |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2013 |
End | 02/2014 |
Description | BRC project grant |
Amount | £60,000 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Newcastle Biomedical Research Centre |
Sector | Academic/University |
Country | United Kingdom |
Start | 01/2009 |
End | 12/2009 |
Description | Capacity Building in Higher Education |
Amount | £700,000 (GBP) |
Organisation | Erasmus + |
Sector | Public |
Country | United Kingdom |
Start | 09/2017 |
End | 09/2020 |
Description | Cell surface marking of corneal epithelial stem cells: a powerful approach to stem cell enrichment prior to transplantation |
Amount | £50,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2017 |
End | 07/2018 |
Description | Chronic Granulomatous Disease project grant |
Amount | £150,000 (GBP) |
Organisation | The Chronic Granulomatous Disorder Society |
Department | Chronic Granulomatous Disorder (CGD) Research Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2010 |
End | 07/2012 |
Description | Corneal epithelial stem cell therapy: enhancing safety and stability of cultured product |
Amount | £120,000 (GBP) |
Organisation | UCL Partners |
Department | UCL Partners AHSC and AHSN |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2014 |
End | 09/2015 |
Description | Demonstrating proof of principle for generating a platform technology to direct differentiation of pluripotent stem cell using Sendai Viral vectors |
Amount | £62,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Department | MRC Confidence in Concept Scheme |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2016 |
End | 08/2017 |
Description | ERC CONSOLIDATOR FELLOWSHIP |
Amount | € 1,300,000 (EUR) |
Funding ID | 614620 |
Organisation | European Research Council (ERC) |
Sector | Public |
Country | Belgium |
Start | 05/2014 |
End | 05/2018 |
Description | European Bank of induced pluripotent stem cells (EbiSC) |
Amount | € 232,500 (EUR) |
Funding ID | EbiSC |
Organisation | European Commission |
Department | Seventh Framework Programme (FP7) |
Sector | Public |
Country | European Union (EU) |
Start | 04/2014 |
End | 09/2016 |
Description | Exploiting the role of exosomes to treat age related macular degeneration and provide biomarkers for early diagnosis of the disease |
Amount | £64,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2017 |
End | 08/2018 |
Description | Fanconi Anaemia Fund project grant |
Amount | £50,000 (GBP) |
Organisation | Fanconi Anemia Research Fund (FARF) |
Sector | Charity/Non Profit |
Country | United States |
Start | 12/2009 |
End | 12/2010 |
Description | Fight for Sight UK project grant |
Amount | £166,000 (GBP) |
Organisation | Fight for Sight |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2009 |
End | 03/2012 |
Description | Fight for Sight project grant |
Amount | £170,000 (GBP) |
Funding ID | 1456/1457 |
Organisation | Fight for Sight |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2013 |
End | 08/2017 |
Description | Generation of disease models for Fanconi Anaemia using pluripotent stem cells |
Amount | £78,000 (GBP) |
Organisation | Leukaemia and Lymphoma Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2011 |
End | 12/2011 |
Description | Investigating haematopoietic development in Ligase IV and XLF patients using induced pluripotent stem cells |
Amount | £166,000 (GBP) |
Organisation | Leukaemia and Lymphoma Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2009 |
End | 04/2012 |
Description | Investigation of the haematopoietic differentiation of human ES cells |
Amount | £146,000 (GBP) |
Organisation | Leukaemia and Lymphoma Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2005 |
End | 07/2008 |
Description | MRC Confidence in Concept Scheme |
Amount | £26,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2016 |
End | 09/2016 |
Description | MRC Integrated Mres/PhD studentship |
Amount | £100,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2012 |
End | 08/2016 |
Description | MRC Translational Stem Cell Research Committee (TSCRC) Grant |
Amount | £1,206,610 (GBP) |
Funding ID | G0900879 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2010 |
End | 03/2015 |
Description | MRC/BBSRC Human iPS cell research project grant |
Amount | £62,500 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2008 |
End | 03/2009 |
Description | MRC/BBSRC Human iPS cell research project grant |
Amount | £625,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2008 |
End | 03/2009 |
Description | Macular Disease Society PROJECT GRANT |
Amount | £170,000 (GBP) |
Organisation | Macular Society |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2014 |
End | 03/2017 |
Description | NOVARTIS PROJECT GRANT |
Amount | £41,400 (GBP) |
Organisation | Novartis |
Sector | Private |
Country | Global |
Start | 03/2012 |
End | 03/2013 |
Description | Newcastle Health Charity project grant |
Amount | £49,000 (GBP) |
Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
Department | Newcastle Healthcare Charity |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2011 |
End | 01/2012 |
Description | Newcastle Health Charity project grant |
Amount | £49,000 (GBP) |
Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
Department | Newcastle Healthcare Charity |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2007 |
End | 12/2007 |
Description | PhD studentship |
Amount | £100,000 (GBP) |
Organisation | Newcastle University |
Department | Dr William Edmund Harker Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2013 |
End | 09/2016 |
Description | RP Fighting Blindness project grant |
Amount | £150,000 (GBP) |
Funding ID | GR584 |
Organisation | RP Fighting Blindness |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2013 |
End | 12/2015 |
Description | Single Cell Genomics Unit |
Amount | £2,000,000 (GBP) |
Funding ID | MR/M008886/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2015 |
End | 12/2015 |
Description | Sir James Knott Trust project grant |
Amount | £600,000 (GBP) |
Organisation | Sir James Knott Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2008 |
End | 12/2008 |
Description | Stem cells for biological assays of novel drugs and predictive toxicology |
Amount | € 2,200,000 (EUR) |
Funding ID | STEMBANCC |
Organisation | European Commission |
Department | Seventh Framework Programme (FP7) |
Sector | Public |
Country | European Union (EU) |
Start | 09/2012 |
End | 09/2017 |
Description | Understanding the role of autophagy in the pathogenesis of AMD using a patient specific iPSC model |
Amount | £170,000 (GBP) |
Organisation | Macular Society |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2017 |
End | 12/2020 |
Title | donor contructs for introducing GFP reporter into the 3' UTR of CRX gene |
Description | a donor construct was made to introduce GFP into the endogenous CRX locus |
Type Of Material | Technology assay or reagent |
Year Produced | 2013 |
Provided To Others? | Yes |
Impact | this will enable other researchers to introduce this reporter into their human ESC and iPSC lines and monitor differentiation process |
Title | human iPSC lines from diseased individuals |
Description | human iPSC lines from patients with Fanconi Anaemia (type C), Ligase IV and XLF deficient patients, CGD patients, Muscular Dystrophy and HLHS patients |
Type Of Material | Cell line |
Year Produced | 2011 |
Provided To Others? | Yes |
Impact | several publications have risen from this work as follows; 22311747 23818183 23722522 23280624 23582880 |
Title | human iPSC lines from patients with PRPF31 mutations |
Description | these are patient specific cell lines generated from reprogramming of adult fibroblasts taken from skin biopsies of PRPF31 patients |
Type Of Material | Cell line |
Year Produced | 2014 |
Provided To Others? | No |
Impact | the availability of this material will enable generation of in vitro disease models |
Description | Testing of monoclonal antibodies |
Organisation | Inova Technology |
Country | United States |
Sector | Private |
PI Contribution | We are very active testing monoclonal antibodies for: Becton Dickinson Miltenyi Biotec Biolegend Biostatus Beta testing software for Applied Cytometry Sheffield (Venturi one software) Inivai Technologies, Victoria Australia (Gatelogic & Flow Logic) This allows us to do three things: 1 Acquire free antibodies from the companies allowing us to thoroughly test the suitability of the antibodies and fluorochromes at no cost to ourselves, in addition we have residual antibody left after this test that, if acceptable, we can use and or distribute to users. 2 Develop a symbiotic relationship with the companies whereby we often get free kits to run our internal user training (such as the Apoptosis course) at no cost in terms of reagents. 3 Because of the relationship we develop we often get asked to give our opinion on newly developed kits , and also , recently train users on instrumentation for Becton Dickinson 4 The ability to try and evaluate software inevitably leads to us acquiring free of charge the software in question and so adding to the users choice of free software available in the core facility. |
Start Year | 2007 |
Description | collaboration with Dr. Saretzki and Prof. von Zglinicki |
Organisation | Newcastle University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are interested in the role of telomerase, DNA damage and oxidative stress in ESC and iPSC as well as their derivatives for disease modelling studies. |
Collaborator Contribution | Our collaborators provide advice and assistance on telomerase, DNA damage and oxidative stress measurement assays. |
Impact | 23818183 23722522 23280624 22311747 20073085 18203676 18055443 15790773 15536187 15511642 |
Start Year | 2006 |
Description | BIO 2008 conference presentation |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Geographic Reach | International |
Primary Audience | Health professionals |
Results and Impact | 30 minutes talk to a large audience (25,000 participants) Radio conference followed the talk |
Year(s) Of Engagement Activity | 2008 |
Description | Core member of committee C, BBSRC |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | member of committee C: reading and reviewing proposals, helping to shape UK policy |
Year(s) Of Engagement Activity | 2017,2018 |
Description | European Commission, Evaluator of REA-FET-OPEN-2017 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | panel member: discuss proposals and reach funding decisions |
Year(s) Of Engagement Activity | 2017 |
Description | European Commission, Member of H02020 panel "Clinical Research on regenerative medicine", June 2017 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | panel member: proposal discussion and selection for funding |
Year(s) Of Engagement Activity | 2017 |
Description | Flow cytometry training course |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | Yes |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Flow cytometry training course: Side population by flow cytometry This course is organised every year: number of participants between 20 and 30. Handbook produced no actual impacts realised to date |
Year(s) Of Engagement Activity | 2007 |
URL | http://www.guardian.co.uk/science/video/2010/mar/31/genetics-autism-zebra-finch |
Description | Member of the H2020-JTI-IMI2-panel |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | Ho2020 panel member: proposal discussion and funding, helping to share EU research policy and funding. |
Year(s) Of Engagement Activity | 2017,2018 |
Description | Member of the H2020: SC1-BHC-09-2018 panel |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | Ho2020 panel member: proposal discussion and funding, helping to share EU research policy and funding. |
Year(s) Of Engagement Activity | 2006,2017 |
Description | Organiser of the Newcastle RP Patient Information Day, 8th June 2016 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | 98 patients and their families attended the event which sparked a lot of questions, discussion and increased interest in application of stem cell therapies for retinal disease. |
Year(s) Of Engagement Activity | 2016 |
URL | https://campus.recap.ncl.ac.uk/Panopto/Pages/Viewer.aspx?id=d7b01a8a-3dfe-486e-b0ae-bc8d02b3e3f9 |
Description | Using stem cells to understand our development and human disease |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Talk no actual impacts realised to date |
Year(s) Of Engagement Activity | 2012 |
Description | stem cell festival |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | Yes |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | about 300 members of the public attended the event we have been asked to participate every year |
Year(s) Of Engagement Activity | 2012,2013,2014 |